Liquidia, the designer and manufacturer of engineered particles, has announced that its collaboration with PATH has been extended to develop next generation Pneumococcal vaccine. The vaccine, if successful, could potentially allow for ...
Tags: Liquidia, Pneumococcal Vaccine
Liquidia Technologies is planning to set up a new ophthalmology-focused company to manufacture products that address the unmet needs, growth therapeutic areas and to maximize the return for its investors. The proposal follows the success ...
Tags: Liquidia, Ophthalmology Company
Liquidia Technologies has initiated multi-year product development collaboration with GlaxoSmithKline (GSK). Under the collaboration, GSK acquired exclusive rights to research and develop certain vaccine and inhaled product candidates ...